narsoplimab

FDA Drug Profile — YARTEMLEA

Drug Details

Generic Name
narsoplimab
Brand Names
YARTEMLEA
Application Number
BLA761152
Sponsor
Omeros Corporation
NDC Codes
2
Dosage Forms
INJECTION, LIQUID
Routes
INTRAVENOUS
Active Ingredients
NARSOPLIMAB

Indications and Usage

1 INDICATIONS AND USAGE YARTEMLEA is indicated for the treatment of adult and pediatric patients 2 years of age and older with hematopoietic stem cell transplant-associated thrombotic microangiopathy (TA-TMA). YARTEMLEA is a MASP-2 inhibitor indicated for the treatment of adult and pediatric patients 2 years of age and older with hematopoietic stem cell transplant-associated thrombotic microangiopathy (TA-TMA). ( 1 )